WHO launches large-scale global COVID-19 clinical trials.

However, it is not easy to obtain clear and strong evidence from these clinical trials to support the efficacy of a particular drug.
the design of different clinical trials may vary, resulting in the results of trials that cannot be compared with each other.
doctors may have no time for clinical trials in areas where the outbreak is under control, and a dwindling number of patients could make recruiting a sufficient number of patients an important obstacle to the trial.
the drug Mingcond Content Team Mapping, the World Health Organization (WHO) developed the master protocol for the treatment of COVID-19 clinical trials, which seeks to standardize the design of clinical trials conducted around the world, allowing researchers to pool data from different clinical trials to produce clearer and stronger evidence.
19, WHO Director General Dr. Tandese announced at a regular press conference that WHO and its partners will conduct a large-scale global clinical trial to test the efficacy of multiple candidate therapies for PATIENTs with COVID-19.
the aim of this large international study is to generate the strong data researchers need to compare which candidates are most effective.
WHO calls it the Solidarity clinical trial. Dr.
, dr. Tandese, noted that several countries have confirmed their participation in the SOLIDARITY clinical trials, including Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, Switzerland and Thailand.
he believes more countries will join the clinical trial.
, Dr. Ana Maria Henao-Restrepo, Medical Officer, Department of Immunovaccines and Biologics of the World Health Organization (WHO Twitter), Director-General of the World Health Organization (WHO) presented the details of the clinical trial.
SOLIDARITY Clinical Trials is a global, multi-arm, randomized controlled adaptive design (adaptive design) clinical trial.
it consists of a control group and four treatment groups.
control group patients receive current standard care in their country, and the other four treatment groups use Redsivir, Lopinavir/Litonevir, Lopinavir/Litonevir, or chloroquine, in addition to standard care.
each country and hospital can choose one or more drugs for clinical trials according to their circumstances.
trials will focus on key factors related to improving patient health, including mortality in PATIENTs with COVID-19, the chance of using mechanical ventilation or intensive care units (ICUs), and length of stay in hospital. Dr.
, dr. Tandese, said the clinical trial was designed to simplify the clinical trial process and allow hospitals with significant medical stress to participate even in the hot spot of an outbreak. Another advantage of adaptive design, added dr.
Henao-Restrepo, is that researchers can add or remove treatment groups on the advice of an independent data watchdog.
following the outbreak of Ebola virus infection, WHO, in conjunction with partners, conducted clinical trials comparing a variety of potential treatments for the Ebola virus.
results of the clinical trial, called PALM, were published late last year in the New England Journal of Medicine (NEJM).
it compared four antibody therapies and small molecule therapies to treat the Ebola virus.
Redsewee was also a treatment option in palm clinical trials.
we look forward to the success of this large-scale international clinical trial, providing researchers with large-scale, high-quality clinical data to identify effective treatments for COVID-19 at an early date.
Appendix: CandidateS in The SOLADARITY Clinical Trials Profile Redsewe: RNA-dependent RNA polymerase (RdRp) inhibitors, used to treat Ebola virus infection, have demonstrated efficacy in preclinical studies for the treatment of coronaviruses.
has not yet been approved for treatment of any disease.
Lopinavir/Litonevir: Antiviral therapy has been approved for HIV infection and is an HIV protease inhibitor.
interferon beta: Interferon is a cytokine produced by the body against pathogen invasion, and interferon beta has been approved for the treatment of multiple sclerosis.
it is also a common complementary therapy for viral infections.
chloroquine: Chloroquine is a common drug for malaria.
original title: Direct comparison of candidate therapeutic efficacy, WHO initiates large-scale global COVID-19 clinical trials.